DepYmed Appoints Peter Van Ess, Pharm.D., Ph.D. as VP of Early Development
By DepYmed, Inc. | August 5, 2016
Dr. Van Ess to Oversee Drug Development of DepYmed’s Programs in Wilson Disease, Rett Syndrome and Oncology
FARMINGDALE, N.Y., August 5, 2021 -- DepYmed Inc., a preclinical-stage pharmaceutical company developing novel therapeutics for multiple indications using protein tyrosine phosphatase 1B (PTP1B) inhibitors and copper chelators, today announced the appointment of pharmaceutical industry veteran Dr. Peter Van Ess as Vice President of Early Development.
"We are pleased to welcome Peter to DepYmed's management team to help drive the development of our numerous programs, including the initiation of clinical trials for our two lead molecules in the coming year," said Andreas Grill, CEO of DepYmed. "Peter brings significant experience and success in drug development over the two decades in the industry and we look forward to Peter continuing that success with DepYmed."
DepYmed is the leading developer of a new class of small molecule inhibitors of PTP1B for the treatment of inflammatory, neurodegenerative and oncology indications with plans to initiate multiple clinical programs in the coming year. DepYmed is advancing a strong pipeline of novel proprietary molecules for new indications in collaboration with Dr. Nicholas Tonks of Cold Spring Harbor Laboratory and scientific cofounder of DepYmed.
Dr. Peter Van Ess has over 30 years of experience in scientific research and management, including 20 years in the global pharmaceutical industry. Before joining DepYmed, Dr. Van Ess served as the Chief Scientific Officer at Proximagen LLC, where he oversaw research and development activities for a portfolio of programs in inflammation, oncology and neurology; and played a large role in the successful spin-out of Proximagen LLC from Upsher-Smith Laboratories and the development and NDA approval of its lead program, Nayzilam®. Dr. Van Ess has held leadership and management positions in Clinical Pharmacology and Development at Upsher-Smith Laboratories, deCODE genetics and Pfizer where he made substantial contributions to numerous INDs/CTAs and NDA/MAA approvals (such as; Inspra® and Daxas®). In 2008, Dr. Van Ess co-founded the strategic drug development consultancy firm, Great Lakes Drug Development which was acquired by Certara in 2013. Dr. Van Ess received his Bachelor of Science Degrees in Bacteriology and Pharmacy and a Doctor of Pharmacy Degree (Pharm.D.) from the University of Wisconsin-Madison and a Ph.D. in Clinical Pharmacology and Experimental Therapeutics from the University of Kentucky-Lexington College of Pharmacy.
"DepYmed’s innovative approach for modulating PTP1B signaling and copper chelation offers exciting and compelling opportunities to develop new treatments for unmet medical needs,” said Dr. Peter Van Ess. “I am excited to join this motivated team advancing scientific discoveries from the bench to the patient’s bedside.”
ABOUT DEPYMED, INC.
DepYmed Inc., is a New York based cancer and rare disease therapeutic development company that was founded to capitalize on the scientific discoveries of the Tonks lab in PTP1B signaling and ways to modulate its role in various human diseases. DepYmed is currently developing a new class of potent, orally bioavailable inhibitors of the PTP1B enzyme as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition, DepYmed has also discovered a novel class of small molecules with copper chelating properties that it is developing as potential therapeutic agents for diseases like Wilson Disease and various cancers. The company is actively developing a deep pipeline of new compounds in these emerging drug classes in collaboration with Cold Spring Harbor Laboratory to exploit their broad therapeutic potential.
Media Contact:
[email protected]
SOURCE DepYmed Inc.
Dr. Van Ess to Oversee Drug Development of DepYmed’s Programs in Wilson Disease, Rett Syndrome and Oncology
By DepYmed, Inc. | August 5, 2016
Dr. Van Ess to Oversee Drug Development of DepYmed’s Programs in Wilson Disease, Rett Syndrome and Oncology
FARMINGDALE, N.Y., August 5, 2021 -- DepYmed Inc., a preclinical-stage pharmaceutical company developing novel therapeutics for multiple indications using protein tyrosine phosphatase 1B (PTP1B) inhibitors and copper chelators, today announced the appointment of pharmaceutical industry veteran Dr. Peter Van Ess as Vice President of Early Development.
"We are pleased to welcome Peter to DepYmed's management team to help drive the development of our numerous programs, including the initiation of clinical trials for our two lead molecules in the coming year," said Andreas Grill, CEO of DepYmed. "Peter brings significant experience and success in drug development over the two decades in the industry and we look forward to Peter continuing that success with DepYmed."
DepYmed is the leading developer of a new class of small molecule inhibitors of PTP1B for the treatment of inflammatory, neurodegenerative and oncology indications with plans to initiate multiple clinical programs in the coming year. DepYmed is advancing a strong pipeline of novel proprietary molecules for new indications in collaboration with Dr. Nicholas Tonks of Cold Spring Harbor Laboratory and scientific cofounder of DepYmed.
Dr. Peter Van Ess has over 30 years of experience in scientific research and management, including 20 years in the global pharmaceutical industry. Before joining DepYmed, Dr. Van Ess served as the Chief Scientific Officer at Proximagen LLC, where he oversaw research and development activities for a portfolio of programs in inflammation, oncology and neurology; and played a large role in the successful spin-out of Proximagen LLC from Upsher-Smith Laboratories and the development and NDA approval of its lead program, Nayzilam®. Dr. Van Ess has held leadership and management positions in Clinical Pharmacology and Development at Upsher-Smith Laboratories, deCODE genetics and Pfizer where he made substantial contributions to numerous INDs/CTAs and NDA/MAA approvals (such as; Inspra® and Daxas®). In 2008, Dr. Van Ess co-founded the strategic drug development consultancy firm, Great Lakes Drug Development which was acquired by Certara in 2013. Dr. Van Ess received his Bachelor of Science Degrees in Bacteriology and Pharmacy and a Doctor of Pharmacy Degree (Pharm.D.) from the University of Wisconsin-Madison and a Ph.D. in Clinical Pharmacology and Experimental Therapeutics from the University of Kentucky-Lexington College of Pharmacy.
"DepYmed’s innovative approach for modulating PTP1B signaling and copper chelation offers exciting and compelling opportunities to develop new treatments for unmet medical needs,” said Dr. Peter Van Ess. “I am excited to join this motivated team advancing scientific discoveries from the bench to the patient’s bedside.”
ABOUT DEPYMED, INC.
DepYmed Inc., is a New York based cancer and rare disease therapeutic development company that was founded to capitalize on the scientific discoveries of the Tonks lab in PTP1B signaling and ways to modulate its role in various human diseases. DepYmed is currently developing a new class of potent, orally bioavailable inhibitors of the PTP1B enzyme as potential novel therapeutics for HER2-positive breast cancer and Rett Syndrome. In addition, DepYmed has also discovered a novel class of small molecules with copper chelating properties that it is developing as potential therapeutic agents for diseases like Wilson Disease and various cancers. The company is actively developing a deep pipeline of new compounds in these emerging drug classes in collaboration with Cold Spring Harbor Laboratory to exploit their broad therapeutic potential.
Media Contact:
[email protected]
SOURCE DepYmed Inc.
Dr. Van Ess to Oversee Drug Development of DepYmed’s Programs in Wilson Disease, Rett Syndrome and Oncology
Shape Divider - Style triangle